Industry Trends

Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies.

What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.

William Looney, Editor-in-Chief, last month took home the award for "Best Commentary"

Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation

Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story

"Tops in Fraud" is a ruinous moniker for pharma-a business so dependent on basic issues of trust, integrity, quality and safety

It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!

The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica

42 of the best new drugs in development–or parked at the FDA

Pharm Exec's Pipeline Report 2018

Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?

Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters-and how they plan to lead the industry through the turbulent times ahead.

As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.

GAO reviews price hikes in branded drugs, FDA opens up to public, and pharma opens its wallet for Haiti. All on this week's Pharma Unplugged.

The industry is a-changing. Here are eight seminal events that describe how.

The latest dealmaking trends: Early-stage is back in favor. There's more money to be made in being acquired than in going public. And license deals are putting more on the back end.